{"id":509502,"date":"2026-03-02T13:33:16","date_gmt":"2026-03-02T13:33:16","guid":{"rendered":"https:\/\/www.newsbeep.com\/ca\/509502\/"},"modified":"2026-03-02T13:33:16","modified_gmt":"2026-03-02T13:33:16","slug":"new-ozempic-style-pill-outperformed-oral-semaglutide-in-major-trial-sciencealert","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ca\/509502\/","title":{"rendered":"New Ozempic-Style Pill Outperformed Oral Semaglutide in Major Trial : ScienceAlert"},"content":{"rendered":"<p>We may have a new champion when it comes to pills that can manage both blood sugar levels and <a href=\"https:\/\/www.sciencealert.com\/im-an-expert-on-weight-loss-here-are-5-truths-you-need-to-know\" rel=\"nofollow noopener\" target=\"_blank\">weight loss<\/a>.<\/p>\n<p>In a phase 3  <a href=\"https:\/\/www.sciencealert.com\/clinical-trials\" class=\"lar_link lar_link_outgoing\" data-linkid=\"73032\" data-postid=\"193635\" rel=\"nofollow noopener\" target=\"_self\">clinical trial<\/a>, once-daily orforglipron outperformed semaglutide tablets, the best-known oral version of the GLP-1 drugs.<\/p>\n<p>GLP-1 (glucagon-like peptide-1) drugs are named after the natural hormone they mimic, helping curb appetite and stimulate insulin release to process sugar more efficiently.<\/p>\n<p>As the active ingredient in <a href=\"https:\/\/www.sciencealert.com\/volunteers-lose-up-to-25-body-weight-in-high-dose-wegovy-trials\" rel=\"nofollow noopener\" target=\"_blank\">treatments such as Wegovy<\/a> and Ozempic, semaglutide has been hugely successful for tackling both  <a href=\"https:\/\/www.sciencealert.com\/diabetes\" class=\"lar_link lar_link_outgoing\" data-linkid=\"73018\" data-postid=\"193635\" rel=\"nofollow noopener\" target=\"_self\">diabetes<\/a> and obesity. However, while it is available in tablet form, <a href=\"https:\/\/doi.org\/10.1177\/87551225241289959\" rel=\"nofollow noopener\" target=\"_blank\">it&#8217;s most effective when taken via injection<\/a>.<\/p>\n<p>The new results, reported by an international team of researchers and funded by Eli Lilly, suggest orforglipron could become a leading oral alternative. Amongst 1,698 trial participants, people taking orforglipron saw bigger <a href=\"https:\/\/www.sciencealert.com\/time-restricted-eating-helps-control-blood-sugar-in-type-2-diabetes\" rel=\"nofollow noopener\" target=\"_blank\">blood sugar<\/a> improvements, and greater average weight loss (6\u20138 percent compared with 4\u20135 percent on semaglutide tablets).<\/p>\n<p>&#8220;Together with <a href=\"https:\/\/doi.org\/10.1056\/nejmoa2505669\" rel=\"nofollow noopener\" target=\"_blank\">previous research<\/a>, the results of the ACHIEVE-3 study suggest that orforglipron represents an important advancement in the oral treatment landscape for type 2 diabetes,&#8221; <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(26)00202-3\" rel=\"nofollow noopener\" target=\"_blank\">write<\/a> the researchers in their published paper.<\/p>\n<p>The buzz has been growing around orforglipron: Another phase 3 trial <a href=\"https:\/\/www.sciencealert.com\/new-diabetes-pill-works-as-well-as-ozempic-for-weight-loss-trial-finds\" rel=\"nofollow noopener\" target=\"_blank\">carried out last year<\/a> saw impressive results from the drug, though in that study it was compared to a  <a href=\"https:\/\/www.sciencealert.com\/what-is-a-placebo\" class=\"lar_link lar_link_outgoing\" data-linkid=\"102371\" data-postid=\"193635\" rel=\"nofollow noopener\" target=\"_self\">placebo<\/a> rather than semaglutide.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2026\/03\/WeightChart.jpg\" alt=\"Weight chart\" width=\"642\" height=\"443\" class=\"wp-image-193639 size-full\"   loading=\"lazy\"\/>Orforglipron performed better in terms of participant weight loss. (Rosenstock et al., The Lancet, 2026)<\/p>\n<p><a href=\"https:\/\/med.uc.edu\/depart\/psychiatry\/research\/clinical-research\/crm\/trial-phases-1-2-3-defined\" rel=\"nofollow noopener\" target=\"_blank\">Phase 3 trials<\/a> are considered a major step towards making drugs available to the public: They include larger groups of people than phase 1 and 2 trials, track benefits and risks, and compare drugs directly against other treatments.<\/p>\n<p>Here, the participants were drawn from 131 different medical research centers and followed for a year. The trial was specifically aimed at people with <a href=\"https:\/\/www.sciencealert.com\/scientists-think-theyve-found-a-new-cause-of-type-2-diabetes\" rel=\"nofollow noopener\" target=\"_blank\">type 2 diabetes<\/a>, though there are plans to develop it as an obesity treatment too, in the future.<\/p>\n<p>Orforglipron has another advantage over semaglutide: It doesn&#8217;t have to be taken on an empty stomach, making it more convenient for people it&#8217;s prescribed to.<\/p>\n<p>The news from the trial wasn&#8217;t all positive for orforglipron, however. More people stopped taking orforglipron (9\u201310 percent) than stopped taking semaglutide (4\u20135 percent) during the trial, which was mostly down to <a href=\"https:\/\/www.sciencealert.com\/these-5-common-medicines-can-carry-hidden-risks-expert-warns\" rel=\"nofollow noopener\" target=\"_blank\">side effects<\/a> described as &#8220;gastrointestinal issues&#8221;.<\/p>\n<p>&#8220;Although the safety profiles of both orforglipron and semaglutide were generally consistent with the GLP-1 receptor agonist class, the incidence of gastrointestinal events, discontinuations due to adverse events, and mean increase in pulse rate were higher with orforglipron than oral semaglutide,&#8221; <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(26)00202-3\" rel=\"nofollow noopener\" target=\"_blank\">write<\/a> the researchers.<\/p>\n<p><a href=\"https:\/\/www.sciencealert.com\/newsletter?utm_source=promo_generic_health\" rel=\"nofollow noopener\" target=\"_blank\"><img decoding=\"async\" src=\"https:\/\/www.newsbeep.com\/ca\/wp-content\/uploads\/2025\/12\/Generic-Health-Promo-Final-642x273.jpg\" alt=\"Subscribe to ScienceAlert's free fact-checked newsletter\" width=\"642\" height=\"273\" class=\"alignnone wp-image-182810 size-medium\"   loading=\"lazy\"\/><\/a><\/p>\n<p>Regulatory approval will be required before orforglipron becomes available generally, but it&#8217;s getting close. The drug is also currently being evaluated as a way to improve <a href=\"https:\/\/www.sciencealert.com\/huge-study-links-99-of-heart-attacks-and-strokes-with-4-risk-factors\" rel=\"nofollow noopener\" target=\"_blank\">cardiovascular health<\/a> (something we&#8217;ve also <a href=\"https:\/\/www.sciencealert.com\/ozempic-could-be-good-for-your-heart-even-if-you-dont-lose-weight\" rel=\"nofollow noopener\" target=\"_blank\">seen with semaglutide<\/a>).<\/p>\n<p>There are now good reasons to believe that orforglipron can be even more effective than semaglutide in treating type 2 diabetes <a href=\"https:\/\/www.sciencealert.com\/to-tackle-our-obesity-crisis-experts-say-everything-we-do-must-change\" rel=\"nofollow noopener\" target=\"_blank\">and obesity<\/a>. The results add to growing evidence that GLP-1 drugs offer <a href=\"https:\/\/www.sciencealert.com\/landmark-study-finds-semaglutide-effectively-treats-serious-liver-disease\" target=\"_blank\" rel=\"noopener nofollow\">numerous other health benefits<\/a>.<\/p>\n<p>That said, the medications already on the market have also been linked to some major side effects: Wegovy, for example, has been connected to <a href=\"https:\/\/www.sciencealert.com\/suicidal-thoughts-prompt-new-warnings-from-health-authorities-for-glp-1-drugs\" rel=\"nofollow noopener\" target=\"_blank\">mental health issues<\/a> and <a href=\"https:\/\/www.sciencealert.com\/new-weight-loss-drugs-under-scrutiny-amid-pancreas-concerns\" rel=\"nofollow noopener\" target=\"_blank\">pancreatic damage<\/a> in the past.<\/p>\n<p>As always, it&#8217;s important that these medications, no matter how convenient and effective, are developed with patient safety as a priority. Trials like this are designed to map that trade-off more clearly, so doctors and regulators can judge where the benefits outweigh the risks.<\/p>\n<p>Related: <a href=\"https:\/\/www.sciencealert.com\/theres-a-surprising-link-between-a-key-nutrient-obesity-and-alzheimers-risk\" rel=\"nofollow noopener\" target=\"_blank\">There&#8217;s a Surprising Link Between a Key Nutrient, Obesity, And Alzheimer&#8217;s Risk<\/a><\/p>\n<p>&#8220;In conclusion, oral orforglipron was non-inferior and superior to semaglutide in terms of efficacy, with meaningful improvements in glycaemic control and weight reduction compared with oral semaglutide in patients with type 2 diabetes, and with larger improvements in cardiometabolic risk factors and simplified administration,&#8221; <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(26)00202-3\" rel=\"nofollow noopener\" target=\"_blank\">write<\/a> the researchers.<\/p>\n<p>The research has been published in <a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(26)00202-3\" rel=\"nofollow noopener\" target=\"_blank\">The Lancet<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"We may have a new champion when it comes to pills that can manage both blood sugar levels&hellip;\n","protected":false},"author":2,"featured_media":509503,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[45,49,48,315],"class_list":["post-509502","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-business","tag-ca","tag-canada","tag-msft-content"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/509502","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/comments?post=509502"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/posts\/509502\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media\/509503"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/media?parent=509502"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/categories?post=509502"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ca\/wp-json\/wp\/v2\/tags?post=509502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}